33342-65-3

Basic information

• Product Name: 2-Chloro-5-methylthiazole
• Synonyms: 2-CHLORO-5-METHYLTHIAZOLE;2-CHLORO-5-METHYLTHIAZOLE(PHENYLOXINDOLE);2-chloro-5-methyl-1,3-thiazole;Thiazole,2-chloro-5-Methyl-
• CAS NO: 33342-65-3
• Molecular Formula: C₄H₄ClNS
• Molecular Weight: 133.6
• Mol File: 33342-65-3.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 202.661 °C at 760 mmHg
• Flash Point: 76.367 °C
• Appearance: /
• Density: 1.331 g/cm³
• Vapor Pressure: 0.411mmHg at 25°C
• Refractive Index: 1.56
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.32±0.10(Predicted)
• CAS DataBase Reference: 2-Chloro-5-methylthiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-5-methylthiazole(33342-65-3)
• EPA Substance Registry System: 2-Chloro-5-methylthiazole(33342-65-3)

Safety Data

• Hazardous Substances Data: 33342-65-3(Hazardous Substances Data)

Usage

General Description

2-Chloro-5-methylthiazole is a chemical compound with the molecular formula C5H6ClNS. It is a colorless to pale yellow liquid with a pungent odor. It is commonly used as a building block in the synthesis of pharmaceuticals, agrochemicals, and fragrances. 2-Chloro-5-methylthiazole is also used in the production of polymer additives and as a reagent in organic synthesis. It is important to handle this compound with care as it can cause irritation to the skin, eyes, and respiratory tract, and may be harmful if ingested or inhaled. It is important to follow proper safety precautions when working with 2-Chloro-5-methylthiazole to minimize the risk of exposure.

InChI:InChI=1/C4H4ClNS/c1-3-2-6-4(5)7-3/h2H,1H3

Upstream product

• 52829-72-8 5-methylene-1,3-thiazolidine-2-thione 
• 6593-86-8 5-methyl-thiazol-2-ylamine; hydrochloride 
• 17626-82-3 5-methyl-3H-thiazole-2-thione 
• 7305-71-7 5-methyl-2-thiazol-2-amine 
• 3034-52-4 2-chlorothiazole 
• 74-88-4 methyl iodide 
• 79307-64-5 5-methyl-2-(3H)thiazolone 

Downstream Products

• 105827-91-6 α-Cl-β-thiazolyl chloride 
• 210576-58-2 2-chloro-5-bromomethylthiazole 
• 3581-89-3 5-methylthiazole 

Relevant articles and documents

Synthesis method of thiamethoxam

The invention relates to the field of compound synthesis, in particular to a synthesis method of an agricultural insecticide thiamethoxam. According to the preparation method of the thiamethoxam provided by the invention, through selecting appropriate reaction raw materials, a new synthetic route is designed, and an intermediate 2-chlorine-5-chloromethyl-thiazole can be prepared at room temperature, so that a cooling device is not needed, the energy is saved, and the reaction yield can be improved.

Direct Transformation of Arylamines to Aryl Halides via Sodium Nitrite and N-Halosuccinimide

A one-pot universal approach for transforming arylamines to aryl halides via reaction with sodium nitrite (NaNO2) and N-halosuccinimide (NXS) in DMF at room temperature under metal- and acid-free condition is described. This new protocol that is complementary to the Sandmeyer reaction, is suggested to involve the in situ generation of nitryl halide induce nitrosylation of aryl amine to form the diazo intermediate which is halogenated to furnish the aryl halide.

CHEMICAL COMPOUNDS ACTING AS PERK INHIBITORS

The invention is directed to substituted pyrrolidinone derivatives. Specifically, the invention is directed to compounds according to Formula X: wherein R41, R42, R43, R44, R45, R46, and R47 are defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer and diseases associated with activated unfolded protein response pathways, such as Alzheimer's disease, stroke, diabetes, Parkinson disease, Huntington's disease, Creutzfeldt- Jakob Disease, and related prion diseases, amyotrophic lateral sclerosis, myocardial infarction, neurodegeneration, cardiovascular disease, atherosclerosis, ocular diseases, and arrhythmias, more specifically cancers of the breast, colon, pancreas and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.